Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 8Myeloid 2Sarcoma 1

Conditions

Myelodysplastic Syndromes 2Myeloproliferative Disorders 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

fludarabine 33Specimen Handling 32Azacitidine 30venetoclax 29Cyclophosphamide 29Biopsy 25fludarabine phosphate 23Whole-Body Irradiation 19Cytarabine 19ruxolitinib 18Mycophenolic Acid 18Busulfan 18Tacrolimus 16asciminib 15Melphalan 14Injections 14Decitabine 14X-Rays 12Stem Cell Transplantation 12Granulocyte Colony-Stimulating Factor 12decitabine and cedazuridine drug combination 11Magnetic Resonance Spectroscopy 11Cyclosporine 11Sirolimus 10Peripheral Blood Stem Cell Transplantation 10Thiotepa 9Filgrastim 9nilotinib 7Methotrexate 7Imatinib Mesylate 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
quizartinib × Myeloid × 90 days × Clear all
NCT04128748 2026-06-02

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
52 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04493138 2026-05-04

Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
30 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡